Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 06, 2020 07:05 ET | Source: Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Announces Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis Did Not Meet Primary Endpoint

Study did not meet primary endpoint of reducing rate of pulmonary exacerbationsLenabasum treatment had a favorable safety profile and was well-toleratedData to be presented at the upcoming North...
May 22, 2020 08:05 ET | Source: Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2020 E-Congress

First abstract highlights pre-clinical data linking lenabasum’s mechanism of action to inhibiting inflammasome activationSecond abstract outlines baseline characteristics of RESOLVE-1 patients in EU ...
December 09, 2019 08:05 ET | Source: Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals to Host Expert Symposium on the Therapeutic Potential of Targeting the Endocannabinoid System

- Live video webcast on Friday, December 13, 2019 from 1:00 PM – 2:30 PM ET Norwood, MA, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the...
June 12, 2019 08:05 ET | Source: Corbus Pharmaceuticals Holdings, Inc.

Lenabasum Open-Label Extension Data to be Presented at EULAR 2019 Continue to Show a Favorable Safety Profile and Improvement in Efficacy Outcomes in Systemic Sclerosis and Dermatomyositis Phase 2 Studies

ACR CRISS score remains ≥ 0.95 (95%) at 21 months in systemic sclerosis open-label extension (OLE) studyCDASI activity score reaches -21.8 points at 16 months in dermatomyositis OLE study81% systemic...
April 18, 2019 08:05 ET | Source: Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Announces Change of Primary Endpoint in Ongoing RESOLVE-1 Phase 3 Study in Systemic Sclerosis in U.S. to ACR CRISS from mRSS Following Meeting with FDA

Phase 3 primary endpoint will now be aligned with that of previous Phase 2 studyACR CRISS is a composite index (composed of multiple outcomes including mRSS) and was secondary endpoint in current...
December 17, 2018 07:00 ET | Source: Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Initiates “DETERMINE” Phase 3 Study in Dermatomyositis

DM is a rare systemic autoimmune disease that affects ~80,000 individuals in the U.S., EU and Japan and has a 5-year mortality rate as high as 30% This marks Company’s second Phase 3 program in rare...